ERBB2 and hepatocellular carcinoma: In 2021, Bertozzi’s group reported GalNAc-LYTACs to degrade target such as EGFR and HER2.378 Their GalNAc-LYTACs effectively ablated EGFR and HER2 in HCC cells depending on the lysosomal system and the internalization of ASGPR.378 Moreover, in 2024, Xu et al. designed EGFR-ATTECs also using the LC3 ligand GW5074 to degrade EGFR, the result indicated that the ATTECs could induce EGFR degradation and exerted anti-proliferative effects with moderated safety.379 These technologies employ distinct mechanisms to target and dismantle EGFR, potentially offering new therapeutic avenues in oncology.